Structure Therapeutics poised for acquisition, says Mizuho's Jared Holz. Cramer advises halting Viking Therapeutics trades. GPCR Therapeutics' stock prices show promising historical data. Oppenheimer's Jay Olson applauds Viking's nearly flawless obesity drug study results. Investors eye Structure Therapeutics as a prime target.